Berg and the Icahn School of Medicine at Mount Sinai announced a pharmaceutical and diagnostic R&D partnership that will leverage the power of multi-omic biology and data analytics to obtain novel insights and potential therapeutics for cancer, central nervous system and endocrine disorders. Over the course of this five-year partnership, Berg will leverage its award-winning Interrogative Biology(TM) platform in combination with Mount Sinai's expertise in big data, advanced analytics and biological network modeling. Berg and Mount Sinai will adopt an innovative risk and return sharing approach, with downstream royalties significantly higher than the industry standard for academia-pharma partnerships.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7,430 JPY | -0.27% | +1.23% | +18.88% |
04-11 | Belc’s Full-Year Profit Rises 11% | MT |
04-11 | Belc CO., LTD. Provides Consolidated and Non Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2025 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.88% | 995M | |
-11.31% | 38.35B | |
+17.54% | 36.77B | |
+8.85% | 33.9B | |
-0.57% | 18.13B | |
+0.19% | 14.43B | |
-10.42% | 14.21B | |
+22.79% | 12.44B | |
-1.15% | 12.2B | |
-.--% | 11.82B |
- Stock Market
- Equities
- 9974 Stock
- News Belc CO., LTD.
- Berg and Icahn School of Medicine a Mount Sinai Announce R&D Partnership for Drug Discovery and Development